228 related articles for article (PubMed ID: 22235915)
1. Met interacts with EGFR and Ron in canine osteosarcoma.
McCleese JK; Bear MD; Kulp SK; Mazcko C; Khanna C; London CA
Vet Comp Oncol; 2013 Jun; 11(2):124-39. PubMed ID: 22235915
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.
Peace BE; Hill KJ; Degen SJ; Waltz SE
Exp Cell Res; 2003 Oct; 289(2):317-25. PubMed ID: 14499632
[TBL] [Abstract][Full Text] [Related]
3. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.
Jo M; Stolz DB; Esplen JE; Dorko K; Michalopoulos GK; Strom SC
J Biol Chem; 2000 Mar; 275(12):8806-11. PubMed ID: 10722725
[TBL] [Abstract][Full Text] [Related]
7. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
8. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
9. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.
Reznik TE; Sang Y; Ma Y; Abounader R; Rosen EM; Xia S; Laterra J
Mol Cancer Res; 2008 Jan; 6(1):139-50. PubMed ID: 18234969
[TBL] [Abstract][Full Text] [Related]
10. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
12. Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells.
Husmann K; Ducommun P; Sabile AA; Pedersen EM; Born W; Fuchs B
Biochem Biophys Res Commun; 2015 Sep; 464(4):1222-1227. PubMed ID: 26210452
[TBL] [Abstract][Full Text] [Related]
13. EGFR transactivates RON to drive oncogenic crosstalk.
Franco Nitta C; Green EW; Jhamba ED; Keth JM; Ortiz-Caraveo I; Grattan RM; Schodt DJ; Gibson AC; Rajput A; Lidke KA; Wilson BS; Steinkamp MP; Lidke DS
Elife; 2021 Nov; 10():. PubMed ID: 34821550
[TBL] [Abstract][Full Text] [Related]
14. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
15. Investigating TrkA expression in canine appendicular osteosarcoma.
Fan TM; Barger AM; Sprandel IT; Fredrickson RL
J Vet Intern Med; 2008; 22(5):1181-8. PubMed ID: 18638015
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Bonine-Summers AR; Aakre ME; Brown KA; Arteaga CL; Pietenpol JA; Moses HL; Cheng N
Cancer Biol Ther; 2007 Apr; 6(4):561-70. PubMed ID: 17495520
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Canine Osteosarcoma Metastasis.
Wilk SS; Zabielska-Koczywąs KA
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807419
[TBL] [Abstract][Full Text] [Related]
18. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
19. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
20. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
